Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company ...

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Eli Lilly’s experimental weight-loss drug retatrutide led to an average weight reduction of up to 28.7%—more than 71 ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...